{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:24Z","timestamp":1787756184991,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/bmt.2016.156","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T14:04:58Z","timestamp":1465826698000},"page":"1441-1448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (\u2a7e60 years)"],"prefix":"10.1038","volume":"51","author":[{"given":"M","family":"Pohlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"G\u00f6rlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Mesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"B\u00fcchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"BFbmt2016156_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","volume":"32","author":"M Stelljes","year":"2014","unstructured":"Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288\u2013296.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/asheducation.V2012.1.49.3798189","volume":"2012","author":"GJ Mufti","year":"2012","unstructured":"Mufti GJ, Potter V . Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology Am Soc Hematol Educ Program 2012; 2012: 49\u201355.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2016156_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","volume":"21","author":"P Vyas","year":"2015","unstructured":"Vyas P, Appelbaum FR, Craddock C . Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 2015; 21: 8\u201315.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016156_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","volume":"120","author":"P Armand","year":"2012","unstructured":"Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905\u2013913.","journal-title":"Blood"},{"key":"BFbmt2016156_CR5","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"SM Devine","year":"2015","unstructured":"Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol 2015; 33: 4167\u20134175.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR6","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249\u20133256.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2016156_CR8","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1002\/cncr.24531","volume":"115","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715\u20134726.","journal-title":"Cancer"},{"key":"BFbmt2016156_CR9","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664\u20133671.","journal-title":"Blood"},{"key":"BFbmt2016156_CR10","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","volume":"24","author":"T Buchner","year":"2006","unstructured":"Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480\u20132489.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T Buchner","year":"2009","unstructured":"Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61\u201369.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/bmt.2011.110","volume":"47","author":"A Gratwohl","year":"2012","unstructured":"Gratwohl A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749\u2013756.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016156_CR13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087\u20131092.","journal-title":"Lancet"},{"key":"BFbmt2016156_CR14","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874\u20131883.","journal-title":"JAMA"},{"key":"BFbmt2016156_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/bmt.2010.145","volume":"46","author":"J Krauter","year":"2011","unstructured":"Krauter J, Wagner K, Stadler M, Dammann E, Zucknick M, Eder M et al. Prognostic factors in allo-SCT of elderly patients with AML. Bone Marrow Transplant 2011; 46: 545\u2013551.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016156_CR16","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878\u20131887.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR17","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1200\/JCO.2007.15.5184","volume":"26","author":"J Schetelig","year":"2008","unstructured":"Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183\u20135191.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.critrevonc.2007.01.004","volume":"64","author":"MY Shapira","year":"2007","unstructured":"Shapira MY, Tsirigotis P, Resnick IB, Or R, Abdul-Hai A, Slavin S . Allogeneic hematopoietic stem cell transplantation in the elderly. Crit Rev Oncol Hematol 2007; 64: 49\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFbmt2016156_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","volume":"127","author":"C Kollman","year":"2015","unstructured":"Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood 2015; 127: 260\u2013267.","journal-title":"Blood"},{"key":"BFbmt2016156_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","volume":"118","author":"AH Elmaagacli","year":"2011","unstructured":"Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402\u20131412.","journal-title":"Blood"},{"key":"BFbmt2016156_CR21","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","volume":"110","author":"SJ Lee","year":"2007","unstructured":"Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576\u20134583.","journal-title":"Blood"},{"key":"BFbmt2016156_CR22","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","volume":"122","author":"M Schmidt-Hieber","year":"2013","unstructured":"Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013; 122: 3359\u20133364.","journal-title":"Blood"},{"key":"BFbmt2016156_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bbmt.2014.02.015","volume":"20","author":"J Mariotti","year":"2014","unstructured":"Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 885\u2013890.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016156_CR24","doi-asserted-by":"publisher","first-page":"e2013026","DOI":"10.4084\/mjhid.2013.026","volume":"5","author":"J El-Cheikh","year":"2013","unstructured":"El-Cheikh J, Devillier R, Crocchiolo R, Furst S, Calmels B, Faucher C et al. Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation. Mediterr J Hematol Infect Dis 2013; 5: e2013026.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"BFbmt2016156_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","volume":"122","author":"ML Green","year":"2013","unstructured":"Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013; 122: 1316\u20131324.","journal-title":"Blood"},{"key":"BFbmt2016156_CR26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/j.1537-2995.2005.00214.x","volume":"45","author":"CG Erker","year":"2005","unstructured":"Erker CG, Steins MB, Fischer RJ, Kienast J, Berdel WE, Sibrowski W et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 1382\u20131390.","journal-title":"Transfusion"},{"key":"BFbmt2016156_CR27","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","volume":"121","author":"ML Sorror","year":"2013","unstructured":"Sorror ML . How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121: 2854\u20132863.","journal-title":"Blood"},{"key":"BFbmt2016156_CR28","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","volume":"33","author":"R Shouval","year":"2015","unstructured":"Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol 2015; 33: 3144\u20133151.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016156_CR29","doi-asserted-by":"crossref","first-page":"LBA-8","DOI":"10.1182\/blood.V126.23.LBA-8.LBA-8","volume":"126","author":"B Scott","year":"2015","unstructured":"Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter DL et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood 2015; 126: LBA-8.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016156","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:27:12Z","timestamp":1648063632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFbmt2016156"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.156","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,13]]},"assertion":[{"value":"13 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}